

Venous thromboembolism and major bleeding in severe and critical COVID-19 hospitalized patients

Veronica Abate,¹ Anita Vergatti,¹ Aniello Casoria,¹ Aquilino Flavio Zarrella,¹ Riccardo Muscariello,² Vincenzo Nuzzo,² Maria Vargas,³ Giuseppe Servillo,³ Paolo Conca,¹ Lanfranco D'Elia,¹ Gabriella Iannuzzo,¹ Pietro Venetucci,⁴ Gianpaolo De Filippo,⁵ Domenico Rendina,¹ Antonella Tufano¹

¹Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy; ²Endocrinology and Nutrition Department, Ospedale del Mare, Naples, Italy; ³Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University of Naples, Italy; ⁴Department of Morphological and Functional Diagnostics, Radiotherapy, Forensic Medicine, Federico II University of Naples, Italy; ⁵Department of Pediatric Endocrinology and Diabetology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, France

Correspondence: Domenico Rendina, Department of Clinical Medicine and Surgery, Federico II University Hospital, Via S. Pansini 5, 80131 Naples, Italy.
Tel.: +39.081.7463585.
E-mail: domenico.rendina@unina.it

Key words: COVID-19, venous thromboembolism, spontaneous muscle hematoma.

Contributions: DR, PC, PV, AT, methodology; AC, AFZ, GS, MV, VN, RM, reviewed data of the cohort; VA, DR, LDE, software and formal analysis; VA, DR, writing - original draft preparation; GI, GDF, supervised the draft preparation; VA, AV, DR, AT, writing final version - review and editing. All authors have read and agreed to the published version of the manuscript.

Conflict of interest: the authors declare no conflict of interest.

Ethics approval and consent to participate: all patients signed an informed consent as part of administrative management. If any patient withdrew their consent, it did not modify the course of the clinical management.

Informed consent: informed consent was obtained from all subjects involved in the study.

Funding: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Received: 24 April 2023.

Accepted: 7 June 2023.

Early view: 5 July 2023.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2024; 94:2617

doi: 10.4081/monaldi.2023.2617

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Venous thromboembolism (VTE) and major bleeding (MB) are life-threatening complications described in COVID-19 hospitalized patients, and they can be considered two sides of the same coin. This retrospective study aims to evaluate the risk factors for VTE and MB in COVID-19 patients admitted to two Italian hospitals. The medical records of all COVID-19 patients (males 139; 62.3%, mean age 67.2±13.6 years, body weight 88.2±20.6 kg) hospitalized from March 11th to July 31st, 2020, at the Federico II University Hospital and the Sea Hospital, Naples, Italy, were analyzed. The COVID-19 patients were classified into four groups: COVID-19 patients developing VTE and/or MB, COVID-19 patients developing only VTE, COVID-19 patients developing only MB, and COVID-19 patients not developing either VTE or MB. During the hospitalization, 53 COVID-19 patients (24.7%; males 40; 75.5%, mean age 67.2±13.6 years, weight 88.2±20.6 kg) developed VTE, 33 COVID-19 patients (15.3%; males 17; 51.5, mean age 67.3±14.9 years, weight 74.1±14.3 kg) developed MB, and 129 COVID-19 patients did not develop either TVP or MB. No parameters to identify severe COVID-19 complicated by VTE and/or MB were found. However, some clinical and biochemical parameters can be evaluated to predict the risk of MB in order to modify the treatment and take prompt action to reduce mortality.

Introduction

Since December 2019, the rapidly growing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 250 million infections worldwide and more than 5 million deaths [1,2]. The clinical features of COVID-19 are variable and systemic, covering a large spectrum of illnesses ranging from asymptomatic infection to severe and critical diseases with clinical signs of respiratory and multiorgan failures, including coagulation abnormalities [3,4], with both hypercoagulability [venous thromboembolism (VTE)] and major bleeding (MB) complications (*i.e.*, gastrointestinal bleeding, hemoptysis, oral bleeding, bleeding from multiple cannulation sites, intracranial hemorrhage, muscle hematomas, pulmonary and renal hemor-

rhages) [5-7]. In addition, the occurrence of VTE and MB together has already been described in other conditions that present with endothelial damage [8], as also observed in COVID-19 [9]. So that, one can be considered the reverse of the other.

Our recent meta-analysis described an increased risk of VTE in patients with COVID-19 compared to patients with other viral pulmonary infections, such as influenza A [10]. This susceptibility is more evident in patients admitted to hospitals [10,11], and because of this, they are usually managed with prophylactic/therapeutic doses of low-molecular-weight heparin (LMWH). On the other hand, bleeding complications have also been reported in COVID-19, both in emergency settings and stable patients, worsening the outcome and challenging anticoagulant management [12,13].

Despite the reduced mortality and morbidity from COVID-19 [14], SARS-CoV2 continues to represent a burden, mostly in cases of severe disease that need hospitalization according to Italian criteria [15]. Given these premises, the prompt identification of risk factors for VTE or MB appears as a key point for effective and efficient management of hospitalized COVID-19 patients.

The study aims to: i) describe the prevalence of VTE and MB; ii) identify the clinical and laboratory factors that contribute to the occurrence of both VTE and MB considered as a whole; iii) describe the differences between patients affected by VTE and by MB; and iv) find out the risk factors for both or any in hospitalized COVID-19 patients. The study was performed in the Campania Region, Southern Italy, a region with a high incidence and prevalence of COVID-19 patients during the SARS-CoV-2 pandemic.

Materials and Methods

Patients

This retrospective study was performed by analyzing the medical records of all COVID-19 patients referred from March 11th to July 31st, 2020, to the Federico II University of Naples and the Sea Hospital of Naples, Italy. All data were obtained as part of administrative management and hospital care, and informed consent was signed by each patient involved in this study.

Severe acute respiratory syndrome coronavirus 2 diagnostic tests

The diagnosis of SARS-CoV-2 infection was performed by nucleic acid amplification tests as a real-time reverse-transcription polymerase chain reaction, and, when necessary, it was confirmed by nucleic acid sequencing to identify the unique sequences of virus RNA according to the World Health Organization criteria [16].

Italian criteria for hospitalization

According to criteria proposed by the Italian National Institute of Health, COVID-19 patients were hospital-admitted when they presented one or more of the following characteristics: i) moderate hypoxemia (arterial oxygen tension <60 mmHg or oxygen saturation <92% in ambient air) or a ratio of arterial oxygen partial pressure to fractional inspired oxygen <300 or pulmonary infiltrates >50%; ii) dyspnea at rest or for mild efforts (*i.e.*, talking); iii) oxygen saturation <90% during a walking test; iv) a modified early warning score ≥ 5 ; v) changes in sensory state or other symptoms or signs of hypoperfusion and/or hypoxia (*i.e.*, anuria, hypotension, acute coronary artery disease, cyanosis) [15].

Venous thromboembolism and major bleeding diagnosis

VTE consists of symptomatic or incidental pulmonary embolism, deep vein thrombosis of the upper or lower extremities, cerebral sinus vein thrombosis, or splanchnic vein thrombosis, confirmed by computed tomography (CT), magnetic resonance, or ultrasound imaging [17,18]. The International Society on Thrombosis and Hemostasis definition of MB was used, defining it as i) fatal bleeding, ii) symptomatic bleeding in a critical area or organ, or iii) bleeding causing a fall in hemoglobin level higher than 2 g/dL, or leading to a transfusion of 2 or more blood units [19].

Data form

A standardized, pre-piloted schedule was used to extract relevant clinical and laboratory data for this study. The extracted information is listed as follows: age, gender, body weight, history of type 1 and type 2 diabetes mellitus, arterial hypertension, coronary heart disease, cancer, peripheral arterial disease (PAD), defined as all arterial diseases other than coronary arteries and the aorta, including the carotid and vertebral, the upper and lower extremities, mesenteric and renal arteries, cigarette smoking, ongoing pregnancy. Laboratory parameters at the admission evaluated for this analysis were: total blood count, estimated glomerular filtration rate, D-dimer, C-reactive protein, procalcitonin (PCT), interleukin (IL)-6, creatine kinase (CPK). Treatments at home, drugs administered during hospitalization (LMWH, antiplatelets agents, steroids), and death were recorded. Patients with incomplete data collection were excluded from the analysis. All data are available for consultation if requested.

Statistical analysis

All statistical analyses were performed using the IBM SPSS Statistics, version 27 (International Business Machines Corporation, Inc., Armonk, NY, USA). Analysis of variance or chi-squared test and Fisher's exact test were used to assess differences between patients who developed and did not develop VTE, and between patients who developed and did not develop MB. Data are expressed as means \pm standard deviation for continuous variables and as absolute, percentage values for discrete variables. A $p < 0.05$ was considered statistically significant.

Results

Overall, in the lapse of time considered, 223 patients (males 139; 62.3%, mean age 67.2 ± 13.6 years, body weight 88.2 ± 20.6 kg) with severe and critical COVID-19 were admitted to the two Neapolitan hospitals. During the hospitalization, 68 COVID-19 patients developed VTE (COVID-VTE) 5.6 \pm 1.4 days after admission, 41 COVID-19 patients developed MB (COVID-MB) 12.7 \pm 2.3 days after admission, and 114 COVID-19 patients did not develop neither VTE nor MB (COVID-C) and were considered controls. The clinical characteristics of patients affected by COVID-19 and VTE or MB considered in one group (COVID-VTE+MB) compared to COVID-C, COVID-MB, and COVID-VTE are reported in Tables 1-3.

COVID-19 patients with venous thromboembolism versus controls

As reported in Table 3, COVID-VTE showed a lower PCT serum level compared to COVID-C. No additional significant differences between COVID-VTE and COVID-C were observed

Table 1. Clinical characteristics of patients affected by COVID-19 at the time of the hospitalization.

	COVID-VTE+MB	COVID-VTE	COVID-MB	COVID-C
Number (n; %)	86; 48.9	53; 24.7	33; 15.3	129; 60.0
Men (n; %)	57; 66.3	40; 75.5 ^b	17; 51.5	82; 63.5
Women (n; %)	29; 33.7	13; 24.5 ^b	16; 48.5	47; 36.4
Age (years)	67.9±14.0	67.2±13.6	67.3±14.9	67.8±13.2
Body weight (kg)	80.6±18.2	88.2±20.6 ^b	74.1±14.3	84.0±21.9
LMWH (n; %)	46; 53.5	28; 52.8	18; 54.5	69; 53.5
Fondaparinux (n; %)	40; 46.5	25; 47.2	15; 45.5	60; 46.5
Antiplatelets (n; %)	24; 27.9	15; 28.3	9; 27.3	43; 33.3
Bacterial infection (n; %)	30; 34.9	10; 18.9 ^b	20; 60.6 ^a	39; 30.2
Mycotic infection (n; %)	6; 6.9	5; 9.4	1; 3.0	11; 8.5

The data are expressed as mean ± standard deviation for continuous variables and as absolute and percentage for discrete variables. COVID-VTE+MB, patients with COVID-19 and venous thrombo-embolism and/or major bleeding; COVID-VTE, patients with COVID-19 and venous thromboembolism; COVID-MB, patients with COVID-19 and major bleeding; COVID-C, control patients, with COVID-19, but without venous thrombo-embolism and/or major bleeding; LMWH, low molecular weight heparin; ^astatistically different when compared to controls; ^bstatistically different when compared to patients with major bleeding.

Table 2. Comorbidities reported in patients affected by COVID-19 at the time of the hospitalization.

	COVID-VTE+MB	COVID-VTE	COVID-MB	COVID-C
Number	86	53	33	129
Hypertension (n; %)	53; 61.6	32; 60.4	21; 63.6	82; 63.6
T2DM (n; %)	26; 30.2	13; 24.5	13; 39.4	37; 28.7
Obesity (n; %)	51; 59.3	37; 69.8 ^b	14; 42.8	32; 24.8
Neoplasm (n; %)	13; 15.1	7; 13.2	6; 18.2	15; 11.6
CAD (n; %)	22; 25.6	13; 24.5	9; 27.3	22; 17.1
PAD (n; %)	30; 34.9	15; 28.3	15; 45.5 ^a	35; 27.1
CKD (n; %)	23; 26.7	12; 22.6	11; 33.3	44; 34.1
Smoking (n; %)	13; 15.1	7; 13.2	6; 18.2	26; 20.2

The data are expressed as absolute and percentage. COVID-VTE+MB, patients with COVID-19 and venous thrombo-embolism and/or major bleeding; COVID-VTE, patients with COVID-19 and venous thrombo-embolism; COVID-MB, patients with COVID-19 and major bleeding; COVID-C, control patients, with COVID-19, but without venous thrombo-embolism and/or major bleeding; T2DM, type 2 diabetes mellitus; obesity, body mass index over 25 kg/m²; Neoplasm, active neoplasm; CAD, coronary artery disease; PAD, peripheral artery disease; CKD, chronic kidney disease, defined as estimated glomerular filtration rate <30 mL/min/1.73m²; Smoking, smoking habits; ^astatistically different when compared to controls; ^bstatistically different when compared to patients with major bleeding.

Table 3. Biochemical characteristics of patients affected by COVID-19 at the time of the hospitalization.

	COVID-VTE+MB	COVID-VTE	COVID-MB	COVID-C
Hb (g/dL)	12.6±1.4	12.1±1.3	11.9±1.1	13.0±1.2
WBC (*10 ³ /μL)	12.1±5.5	13.2±7.5	10.7±4.2	11.7±5.4
Neutrophils (*10 ³ /μL)	10.3±5.1	11.1±5.8	9.5±3.8	10.5±5.2
Lymphocytes (*10 ³ /μL)	1.4±3.3	1.6±4.6	0.7±0.5	2.3±4.1
Platelets (*10 ³ /μL)	264.2±125.7	268.5±130.9	244.1±121.9	262.5±111.1
CRP (mg/L)	47.9±72.7	39.7±75.2	61.6±62.0	46.5±72.4
PCT (ng/mL)	1.3±2.5	0.4±0.9 ^{a,b}	1.5±3.0	1.4±3.1
IL-6 (pg/mL)	46.9±55.2	39.0±40.8	55.1±67.4	47.2±68.0
PT (sec)	14.4±5.9	14.3±7.4	13.8±3.8	14.4±5.9
PTT (sec)	28.1±3.9	27.2±4.5	27.8±3.4	29.0±4.3
Fibrinogen (g/dL)	637.6±222.1	617.9±203.8	581.3±214.8	658.5±222.6
D-dimer (mg/L)	4.4±3.2	3.6±3.4	2.9±3.5	5.5±3.5
Creatinine (md/dL)	2.9±1.1	1.9±2.3	1.3±1.0	3.0±1.1
Glucose (mg/dL)	134.5±82.0	187.4±102.4	173.1±74.5	134.6±71.0
AST (U/L)	49.6±75.1	42.9±25.4	79.2±256.7	44.2±51.2
LDH (U/L)	494.4±254.3	522.6±215.8	443.5±284.4	493.5±259.3
CPK (μg/L)	431.9±230.1	73.5±149.7 ^b	2155.5±556.6 ^a	136.6±149.7

The data are expressed as mean ± standard deviation. COVID-VTE+MB, patients with COVID-19 and venous thromboembolism and/or major bleeding; COVID-VTE, patients with COVID-19 and venous thromboembolism; COVID-MB, patients with COVID-19 and major bleeding; COVID-C, control patients, with COVID-19, but without venous thrombo-embolism and/or major bleeding; Hb, hemoglobin; WBC, white blood cell count; CRP, C-reactive protein; PCT, procalcitonin; IL-6, interleukin 6; PT, prothrombin time; PTT, partial thromboplastin time; LDH, lactic dehydrogenase; ASP, aspartate amino-transferase; CPK, creatine kinase; ^astatistically significant when compared to controls; ^bstatistically significant when compared to patients with major bleeding.

COVID-19 patients with major bleeding versus controls

At the time of in-hospital admission, COVID-MB showed higher prevalence of bacterial infection [OR 3.55 (1.61-7.85), $p < 0.01$, Table 1] and of PAD [odds ratio (OR) 2.24 (1.02-4.92), $p < 0.04$, Table 2] compared to COVID-C. During the in-hospital course, COVID-MB patients showed significantly higher CPK serum levels compared to COVID-C, as reported in Table 3. COVID-MB patients also presented a higher risk of in-hospital death compared to COVID-C [OR 3.51 (1.59-7.73), $p < 0.01$].

COVID-19 patients with venous thromboembolism versus COVID-19 patients with major bleeding

COVID-VTE patients showed a higher prevalence of men [OR 2.90 (1.15-7.31), $p < 0.04$, Table 1], and obesity [OR 1.65 (1.07-2.54), $p < 0.01$, Table 2] compared to COVID-MB. COVID-MB showed a higher prevalence of bacterial infection [OR 6.62 (2.48-17.63), $p < 0.01$, Table 1] compared to COVID-VTE. COVID-MB patients showed a higher PCT and CPK serum levels compared to COVID-VTE, as reported in Table 3. COVID-MB patients presented a higher risk of in-hospital death compared to COVID-VTE [OR 3.44 (1.38-8.57), $p < 0.01$].

Noteworthy, 2 COVID-patients (0.9%) showed both VTE and MB, with VTE preceding MB, in particular, spontaneous muscle hematoma (SMH). The first patient was a 58-year-old man, and the other patient was a 73-year-old woman, already described in a previous article by the same authors [20]. They were admitted to the Federico II intensive care unit because of the severe COVID-19, and both required non-invasive ventilation support. They developed VTE after 5 and 7 days from the admission respectively and were both treated with LMWH at a therapeutic dose. On the 7th and 10th day, respectively, SMH with hemodynamic instability occurred. The SMH interested the ileo-psoas muscle in the first patient and the vastus intermedius muscle in the second patient. The patients were treated with arterial embolization guided by CT, blood transfusion, and interruption of anticoagulant therapy. However, both patients died, on the 10th and 15th day after the admission, respectively.

Discussion

VTE and MB are two potentially lethal conditions that can complicate the clinical course of COVID-19 patients, in particular in cases of hospitalization, and can be considered two features of the same condition [8,21]. This retrospective study was performed comparing the clinical and biochemical parameters of all consecutive COVID-19 patients admitted to two Italian hospitals, classified according to the development of VTE (COVID-VTE), MB (COVID-MB), or neither (COVID-C) during the in-hospital course. The study results indicate that MB is the complication with the highest mortality risk and that clinical and biochemical characteristics allow to draw a risk profile of patients admitted for COVID-19 into the hospital for the eventual occurrence of MB. COVID-MB presented indeed with bacterial infection and with higher PCT and CPK serum levels. In addition, two patients presented with both VTE and MB.

For the first time, the VTE and MB incidences were evaluated in the same study cohort. A plethora of clinical and experimental evidence demonstrated that the overproduction of early response proinflammatory cytokines (tumor necrosis factor, IL-6, and IL-

1 β), resulting in a “cytokine storm”, is the leading cause of the systemic complications reported in severe and critical COVID-19 diseases [20]. In particular, the cytokine storm significantly impacts the effects of COVID-19 on the vascular system, actively contributing to vascular damage, complement activation, and coagulation activation [22]. In addition, the cytokine storm triggers the hemostasis system by increasing the fibrinolysis inhibitor on one side and the tissue factor on the other [23]. These can lead to the reported episodes of VTE and MB complications that complicate the COVID-19 course. The occurrence of either VTE and/or MB was associated with excess mortality, highlighting the importance of developing effective prevention and treatment strategies that reduce their frequency [24,25].

Katsoularis *et al.* described COVID-19 as an independent risk factor for VTE and MB [26], although they failed to determine other co-factors that can interact with SARS-CoV2 infection in the determination of either thrombotic or hemorrhagic complications. The clinical implication could be represented by the encouragement of a more precautionary approach in therapeutic management, making the balance tip one way or another.

The study has several strengths. We found that some clinical parameters and biomarkers are associated with the risk of MB in severe and critical COVID-19 hospitalized patients. They are quick to obtain in an emergency setting and affordable in any place. These parameters are already known to predict a poor outcome in COVID-19 patients and are commonly evaluated at hospital admission. Given these premises, prompt identification of COVID-19 patients at increased risk of MB can make it easier to manage in an emergency. Our study encompasses some limitations. The retrospective nature fails to define a causal connection and allows it to describe just the association of the variables, which can be considered a limitation.

Conclusions

In conclusion, even if MB and VTE share the same pathogenesis, our data did not clarify a risk profile for patients affected by COVID-19 and complicated by any coagulopathy. However, MB is a complication of the SARS-CoV2 infection that impacts survival. Some clinical and biochemical parameters can be evaluated to predict the risk of such a condition, so as to tailor antithrombotic treatment to each fragile patient. Furthermore, the results of this study may also be helpful in acknowledging the clinical complications that may affect subjects with a unique risk profile in cases of viral infections resembling SARS-CoV2, such as influenza viruses [10].

References

1. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514-23.
2. World Health Organization. COVID-19 dashboard. Available from: <https://covid19.who.int/>.
3. Gattinoni L, Gattarello S, Steinberg I, et al. COVID-19 pneumonia: pathophysiology and management. *Eur Resp Rev* 2021;30:210138.
4. Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. *Intern Emerg Med* 2020;15:1375-87.
5. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial

- thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res* 2020;91:9-14.
6. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care* 2020;46:1089-98.
 7. Fraissé M, Logre E, Pajot O, et al. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French mono-center retrospective study. *Crit Care* 2020;24:275.
 8. Henderson SR, Salama AD. Haemorrhage and thrombosis: tackling two sides of a single vasculitic disease. *Nephrol Dial Transplant* 2012;27:4243-4.
 9. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. *Acta Pharmacol Sin* 2023;44:695-709.
 10. Tufano A, Rendina D, Abate V, et al. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: a systematic review with meta-analysis. *J Clin Med* 2020;10:4925.
 11. Shah A, Donovan K, McHugh A, et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. *Crit Care* 2020;24:561.
 12. Abate V, Casoria A, Rendina D, et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. *Semin Thromb Hemost* 2021;48:100-8.
 13. Deitelzweig S, Luo X, Nguyen JL, et al. Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. *J Thromb Thrombolysis* 2022;53:766-76.
 14. Willan J, Agarwal G, Bienz N. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients. *Br J Haematol* 2023;201:640-4.
 15. Agenzia Nazionale per i Servizi Sanitari Regionali. Criteri di appropriatezza per i setting assistenziali di gestione ospedaliera dei pazienti affetti da COVID-19 – Ver. 2.0. Available from: https://www.agenas.gov.it/images/agenas/covid-19/ Appropriatezza_setting_ospedalieri_COVID_2.0_17_6_2021.pdf. [Text in Italian].
 16. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Available from: <https://apps.who.int/iris/handle/10665/331501>.
 17. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. *J Thromb Haemost* 2013;11:412-22.
 18. Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. *J Thromb Haemost* 2016;14:1696-710.
 19. Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13:2119-26.
 20. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. COVID-19 infection: an overview on cytokine storm and related interventions. *Virol J* 2022;19:92.
 21. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:844-7.
 22. Chen R, Lan Z, Ye J, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration. *Front Immunol* 2021;12:589095.
 23. Aires RB, Soares AASM, Gomides APM, et al. Thromboelastometry demonstrates endogenous coagulation activation in nonsevere and severe COVID-19 patients and has applicability as a decision algorithm for intervention. *PLoS One* 2022;17:e0262600.
 24. Burn E, Duarte-Salles T, Fernandez-Bertolin S, et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. *Lancet Infect Dis* 2022;22:1142-52.
 25. Altschul DJ, Unda SR, de La Garza Ramos R, et al. Hemorrhagic presentations of COVID-19: risk factors for mortality. *Clin Neurol Neurosurg* 2020;198:106112.
 26. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. *BMJ* 2022;377:e069590.